The Institute of Pharmacology and Structural Biology (IPBS-Toulouse, CNRS-UT3) in France is inviting applications for a PhD position in the field of epigenetic mechanisms in cancer. The position is offered in the research group led by Priyanka Sharma, a team leader with extensive expertise in transcriptional regulation and chromatin biology. The group focuses on understanding the functional role of arginine citrullination in transcriptional plasticity and immune regulation in cancer, aiming to uncover new therapeutic strategies for cancer patients.

The research will investigate how post-translational modifications, particularly arginine citrullination mediated by peptidyl arginine deiminases (PADIs), influence gene regulation and oncogenesis. The team employs advanced multidisciplinary approaches, including single-cell omics, microscopy, proteomics, and CRISPR-Cas9 genome editing, to dissect the molecular mechanisms underlying transcriptional events and immune hijacking in cancer. The lab's work is highly collaborative, with partnerships across Europe, and is supported by a strong publication record in leading journals.

Applicants should be final-year master's students with a background in molecular biology, genetics, biochemistry, or related disciplines. Experience with relevant techniques and a passion for research in epigenetics and cancer biology are highly valued. The position is based in Toulouse, in the south of France, offering a vibrant scientific environment and access to state-of-the-art facilities.

While specific funding details are not provided, PhD positions at CNRS institutes are typically fully funded, covering stipend and tuition. Interested candidates should contact Priyanka Sharma before March 10, 2026, to discuss their interest and suitability for the role. For more information about the research theme, visit the lab's webpage.

Keywords: epigenetics, cancer, transcription regulation, arginine citrullination, RNA polymerase II, chromatin, gene regulation, immune regulation, single-cell omics, CRISPR-Cas9, proteomics.